← Eichor
Study identifier: NCT06933199 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis

Condition: Brain Metastases  ·  Sponsor: University Hospital Ostrava

PhaseNA
Planned participants260
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the Czech neurooncology network. Most relevant studies published to date used single-fraction radiotherapy and dealt with the inherent bias related to their retrospective nature. The researchers aim to increase the level of evidence for this treatment paradigm together with other similar ongoing studies.

This description comes directly from the study's public registry record.

Talk to the study team

Jiří Hynčica  ·  0042059737  ·  jiri.hyncica@fno.cz

Always discuss trial participation with your own doctor first.

Locations (4)

University Hospital OstravaOstrava, Moravian-Silesian Region, CzechiaRecruiting
Masaryk Memorial Cancer InstituteBrno, CzechiaRecruiting
University Hospital Hradec KrálovéHradec Králové, CzechiaRecruiting
University Hospital OlomoucOlomouc, CzechiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06933199